Hodgkin Lymphoma A Comprehensive Overview 2021 Edition at Meripustak

Hodgkin Lymphoma A Comprehensive Overview 2021 Edition

Books from same Author: Andreas Engert , Anas Younes

Books from same Publisher: Springer

Related Category: Author List / Publisher List


  • Retail Price: ₹ 11723/- [ 0.00% off ]

    Seller Price: ₹ 11723

Sold By: T K Pandey      Click for Bulk Order

Offer 1: Get ₹ 111 extra discount on minimum ₹ 500 [Use Code: Bharat]

Offer 2: Get 0.00 % + Flat ₹ 100 discount on shopping of ₹ 1500 [Use Code: IND100]

Offer 3: Get 0.00 % + Flat ₹ 300 discount on shopping of ₹ 5000 [Use Code: MPSTK300]

Free Shipping (for orders above ₹ 499) *T&C apply.

In Stock

Free Shipping Available



Click for International Orders
  • Provide Fastest Delivery

  • 100% Original Guaranteed
  • General Information  
    Author(s)Andreas Engert , Anas Younes
    PublisherSpringer
    ISBN9783030324841
    Pages509
    BindingPaperback
    LanguageEnglish
    Publish YearAugust 2021

    Description

    Springer Hodgkin Lymphoma A Comprehensive Overview 2021 Edition by Andreas Engert , Anas Younes

    This book, now in its third edition, examines the current treatment options for first-line, relapsed, and refractory Hodgkin lymphoma and the appropriate management in special clinical circumstances, including in the elderly, pregnant women, and those with nodular lymphocyte-predominant disease (NLPHL). Careful attention is devoted to the emerging individually tailored treatment strategies, including checkpoint inhibition, that are especially appealing given their potential to reduce early and late treatment side effects in this generally young patient population. In addition, clear guidance is provided on the management of Hodgkin survivors. Other topics addressed include epidemiology, pathogenesis, the role of the microenvironment, initial clinical evaluation, imaging diagnosis, use of staging systems, and prognostic factors. The new edition of Hodgkin Lymphoma: A Comprehensive Overview has been revised and updated by key opinion leaders to reflect recent progress in the field. It will be of great value to hematologists, oncologists, and all others with an interest in Hodgkin lymphoma.